Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels

For patients with locally advanced prostate cancer, combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen (PSA) levels, compared to hormonal therapy alone, reports a study in the April issue of The Journal of Urology, an Official Journal of the American Urological Association.

Opinion | Three Tools to Address Health Equity

N. Adam Brown is a practicing emergency physician, entrepreneur, and healthcare executive. He is the founder of ABIG Health, a healthcare growth strategy firm, and

February 26, 2024

This Drug Class Keeps AA Amyloidosis in Check

One of the most serious complications of rheumat0logic and autoimmune diseases can be prevented with biologic drugs, a single-center chart review suggested, and some such

July 23, 2024

Diabetes Drugs Overpriced; Hormone Drugs and Brain Tumors; Menopause or Herpes?

Insulins, SGLT2 inhibitors, and GLP-1 receptor agonists can likely be manufactured for prices “far below” their current prices, according to an economic evaluation of manufacturing

April 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.